|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Until recently, the combination of beta-blockers, reninangiotensin system inhibitors (angiotensin converting enzyme (ACE)-inhibitors or angiotensin receptor blockers (ARBs)), and mineralocorticoid receptor antagonists (MRAs) formed the foundation of "triple therapy" for heart failure.
|
31736333 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Treat HF with ACE inhibitors and β-blockers.
|
28602366 |
2017 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To this date, pharmacotherapy for HF has mainly focused on chronic HF with reduced ejection fraction (HFrEF), with angiotensin converting enzyme inhibitors (ACEi) being at the centre of the management plan, alongside angiotensin-receptor-blockers (ARBs), β-blockers (BB) and mineralocorticoid receptor antagonists (MRAs).
|
30931184 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
To examine associations of below-target and target dose of enalapril, an angiotensin-converting enzyme (ACE) inhibitor, with outcomes in patients with heart failure and reduced ejection fraction (HFrEF) in the Studies of Left Ventricular Dysfunction (SOLVD) Treatment trial.
|
28980368 |
2018 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To determine the distribution of angiotensin-converting enzyme genetic polymorphism variants and their relation with echocardiographic outcome of patients with non-ischemic heart failure.
|
24270863 |
2014 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To determine ACE polymorphism in patients with HF secondary to Chagas disease and patients with Chagas disease without systolic dysfunction, and to evaluate the relationship of the ACE polymorphism with different clinical variables.
|
28977050 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
To calculate estimated 5-year number needed to treat (NNT) values overall and for different subpopulations for the Prospective Comparison of ARNI with Angiotensin-Converting Enzyme Inhibitor (ACEI) to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) cohort.
|
30484837 |
2018 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To assess the frequency of ACE gene polymorphisms in patients with ischemic HF in a Rio de Janeiro population, as well as its association with echocardiographic findings.
|
27812677 |
2016 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To assess the clinical effectiveness of beta-blocker therapy in individuals with heart failure (HF) and chronic lung disease and of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) in individuals with HF and chronic kidney disease.
|
28873219 |
2017 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Thus, the expression of the cardiac ACE but not of human heart chymase is upregulated in failing human heart indicating an activation of the cardiac renin-angiotensin system in patients with advanced heart failure.
|
8040271 |
1994 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, the ability of ACE-inhibitors and ARBs to modulate the vascular phenotype, to preserve normal flow mediated vasodilatation may explain the beneficial effects of these drugs compared to other forms of afterload reduction in the treatment of heart failure.
|
19357768 |
2009 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Three HF cardiologists developed an HF Medication Score (HFMS) to quantify adequacy of dosages of β blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers and mineralocorticoid receptor antagonists.
|
27912890 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study aims to investigate the eligibility of the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor (ARNI) with ACE inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) study to a real-world heart failure population.
|
29345425 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thirty beta-blocker and 10 ACE inhibitor pharmacogenetic studies in patients with HF were identified.
|
22464776 |
2012 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These results add evidence for an association of the DD genotype of the angiotensin-converting enzyme gene with earlier onset of symptoms and decreased survival rate of selected patients with heart failure.
|
15721506 |
2005 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
These patients have neurohormonal activation like that of HF with reduced ejection fraction; however, beta-blockers and angiotensin-converting enzyme inhibitors have not been shown to improve their outcomes, and current treatment for these patients is symptom based and empiric.
|
29283224 |
2018 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest a potential pharmacogenetic interaction between the ACE D/I polymorphism and therapy with beta-blockers in the determination of heart failure survival.
|
11273991 |
2001 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings might explain the remarkable benefits of ACE inhibition in the treatment of heart failure.
|
11168675 |
2000 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
There is currently no consensus on the effect of treatment with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), on the prognosis of patients with heart failure and preserved ejection fraction (HFpEF).
|
30694579 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therapy with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) is a mainstay of treatment for heart failure (HF), diabetes mellitus (DM) and chronic kidney disease (CKD).
|
31663151 |
2020 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therapeutic drug monitoring of angiotensin-converting enzyme inhibitors has a great impact on blood pressure control in patients with heart failure and hepatic and renal impairment.
|
30109716 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The treatment of heart failure has changed with the use of angiotensin-converting enzyme inhibitors (ACEIs) and beta-blockers since the middle of the 1990s.
|
30876708 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The target of the current study was to examine the possible cardioprotective effect of telmisartan (Tel), an angiotensin II type 1 receptor (AT1R) blocker, compared with that of captopril (Cap), an angiotensin converting enzyme (ACE) inhibitor, in ameliorating PRG-induced HF in rats by assessing morphometric, echocardiographic and histopathological parameters.
|
31629013 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The status of GDMT at the time of discharge (prescription of angiotensin converting enzyme inhibitor [ACE-I]/angiotensin receptor blocker [ARB] and β blocker [BB]) and its association with 1-year all-cause mortality and HF readmission were investigated.
|
29477488 |
2018 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The significant advances in medical therapy for heart failure over the past 30 years (β-blockade, angiotensin converting enzyme inhibitors, internal cardiac defibrillator and so on) also mandated a reevaluation of the potential benefits of surgical revascularization in this high-risk subset.
|
28834793 |
2017 |